Sandoz And Ares Extend AMR Collaboration Ahead Of Next Phase
Initial December 2018 Agreement Extended Until January 2025
Executive Summary
With plans to enable genomic surveillance for antimicrobial resistant pathogens using Ares’ next-generation sequencing and bioinformatics technologies, the OpGen subsidiary and Sandoz have shaken hands on an extension to their initial master services agreement.
You may also be interested in...
AMR Industry Alliance Publishes Manufacturing Standard
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.
AMR Industry Alliance Publishes Manufacturing Standard
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.